Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2017 | Highlights from ICML 2017: The CLL2-BAG study

Barbara Eichhorst • 14 Jun 2017
ICML 2017
Chronic Lymphocytic Leukemia Bendamustine Obinutuzumab Venetoclax

Barbara Eichhorst, MD, from the University Hospital Cologne, Germany, discusses the CLL2-BAG trial from the German CLL study group (GCLLSG), in her opinion, one of the highlights from the International Conference on Malignant Lymphoma (ICML) 2017 held in Lugano, Switzerland. Looking at treatment naïve and relapsed chronic lymphocytic leukemia (CLL), patients received sequential treatment with bendamustine, obinutuzumab, and venetoclax. Results from this trial have been excellent, with patients responding well, experiencing good tolerability and showing high rates of minimal residual disease.

More from Barbara Eichhorst

1:05
Risk-factors for Richter’s transformation
Barbara Eichhorst • 10 Dec 2023
2:01
Updated follow-up results of the Phase III GAIA/CLL13 trial
Barbara Eichhorst • 10 Dec 2023
2:08
CLL-RT1 trial: primary endpoint analysis of tislelizumab plus zanubrutinib in patients with RT
Barbara Eichhorst • 10 Dec 2023
1:14
Current trials of interest in CLL
Barbara Eichhorst • 7 Oct 2023

Related Videos

3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
3:18
A Phase I study of JBH492, an anti-CCR7 antibody-drug conjugate, in lymphoid malignancies
Pau Abrisqueta • 5 Apr 2024
0:44
Early detection and interception across hematological cancers
Irene Ghobrial • 8 Apr 2024
1:21
Monoclonal B-cell lymphocytosis: a disease to be (or not to be)
Paolo Ghia • 7 Apr 2024
The content of VJHemOnc is intended for healthcare professionals